412308-45-3

Basic information

• Product Name: 5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE
• Synonyms: TIMTEC-BB SBB007140;ART-CHEM-BB B022001;5-CHLORO-2-PIPERIDIN-1-YLANILINE;5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE;AKOS B022001;AKOS BBS-00001428;AKOS BB/0088
• CAS NO: 412308-45-3
• Molecular Formula: C₁₁H₁₅ClN₂
• Molecular Weight: 210.7
• Mol File: 412308-45-3.mol

Chemical Properties

• Melting Point: 49.5-50 °C
• Boiling Point: 188-192 °C(Press: 18-20 Torr)
• Appearance: /
• Density: 1 +-.0.06 g/cm3(Predicted)
• PKA: 6.35±0.11(Predicted)
• CAS DataBase Reference: 5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE(412308-45-3)
• EPA Substance Registry System: 5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE(412308-45-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 412308-45-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to contribute to the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE is utilized as a building block for the creation of novel chemical entities that may possess therapeutic potential.
Used in Drug Discovery:
5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE is employed in drug discovery processes to explore its potential in forming the basis of new drug candidates, given its structural properties and reactivity.
Used in Research Chemicals:
5-CHLORO-2-PIPERIDIN-1-YL-PHENYLAMINE is also used in the production of research chemicals, where it may be involved in experimental studies aimed at understanding its properties and potential applications in medicine.

Upstream product

• 33784-44-0 1-(4-chloro-2-nitrophenyl)piperidine 
• 345-18-6 2-fluoro-5-chloronitrobenzene 

Downstream Products

• 116495-98-8 acetic acid-(5-chloro-2-piperidino-anilide) 

Relevant articles and documents

Optimisation of 2-(N-phenyl carboxamide) triazolopyrimidine antimalarials with moderate to slow acting erythrocytic stage activity

Malaria is a devastating parasitic disease caused by parasites from the genus Plasmodium. Therapeutic resistance has been reported against all clinically available antimalarials, threatening our ability to control the disease and therefore there is an ongoing need for the development of novel antimalarials. Towards this goal, we identified the 2-(N-phenyl carboxamide) triazolopyrimidine class from a high throughput screen of the Janssen Jumpstarter library against the asexual stages of the P. falciparum parasite. Here we describe the structure activity relationship of the identified class and the optimisation of asexual stage activity while maintaining selectivity against the human HepG2 cell line. The most potent analogues from this study were shown to exhibit equipotent activity against P. falciparum multidrug resistant strains and P. knowlesi asexual parasites. Asexual stage phenotyping studies determined the triazolopyrimidine class arrests parasites at the trophozoite stage, but it is likely these parasites are still metabolically active until the second asexual cycle, and thus have a moderate to slow onset of action. Non-NADPH dependent degradation of the central carboxamide and low aqueous solubility was observed in in vitro ADME profiling. A significant challenge remains to correct these liabilities for further advancement of the 2-(N-phenyl carboxamide) triazolopyrimidine scaffold as a potential moderate to slow acting partner in a curative or prophylactic antimalarial treatment.

Synthesis of Quinone Derivatives of Benzannelated Heterocycles with Bridgehead Nitrogen

Abstract: A facile synthesis of para-quinones derived from fused benzimidazoles with a bridgehead nitrogen atom was developed. The heterocyclic quinone core formed as a result of reductive cyclization of ortho-nitroarenes containing alicyclic and aromatic azaheterocycles. Functionalization of 1,2,3,4-tetrahydro- and pyrido[1,2-a]benzimidazoles via SEAr, condensation, and reduction reactions allowed synthesis of amino derivatives which were oxidized with KNO3 in H2SO4 to obtain novel heterocyclic quinones.

METHOD OF REGULATING PHOSPHORYLATION OF SR PROTEIN AND ANTIVIRAL AGENTS COMPRISING SR PROTEIN ACTIVITY REGULATOR AS THE ACTIVE INGREDIENT

The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhi